Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth | Ctech
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - BNN Bloomberg
Teva Cedes Spot as Israel's Biggest Firm in Blow to Prestige - Bloomberg
TEVA, ENDO, MNK Shares Sink After JNJ Opioid Ruling - Bloomberg
Sanofi to Pay Teva as Much as $1.5 Billion for Bowel Drug - Bloomberg
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva considers sale of its active ingredients unit: Bloomberg - YouTube
Teva's CEO Was $2.8 Billion Down on His Second Day on the Job - Bloomberg
Teva Stares Into Abyss as It Slashes Forecast, Dividends - Bloomberg
Teva to Sell Assets Such as Women's Health Unit to Cut Debt - Bloomberg
The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva - Bloomberg
Opioid Epidemic: Drug Wholesalers, Teva Settle With Ohio Counties - Bloomberg
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Teva Pharmaceutical Industries Third Quarter 2022 Earnings: Misses Expectations
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider (NYSE:TEVA) | Seeking Alpha
Teva considering potential sale of inflammatory bowel disease asset - Bloomberg
Teva Up on NYSE Following Morgan Stanley Stock Recommendation Upgrade | Ctech
Teva Pharmaceutical $TEVA Investment Report
Teva's Stock Jumps Following Report on Planned Cuts | Ctech
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
MarketGauge.com
Teva Says 2018 Profit Will Keep Falling as Generic Drug Slump Persists - Bloomberg
